Zai Lab (NASDAQ:ZLAB) CEO Sells $130,191.78 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 7,026 shares of Zai Lab stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $18.53, for a total transaction of $130,191.78. Following the sale, the chief executive officer owned 1,203,784 shares in the company, valued at approximately $22,306,117.52. The trade was a 0.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Friday, June 26th, Ying Du sold 24,543 shares of Zai Lab stock. The stock was sold at an average price of $17.46, for a total transaction of $428,520.78.
• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $20.09, for a total transaction of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Price Performance

Shares of ZLAB stock opened at $19.12 on Friday. The company’s fifty day simple moving average is $18.89 and its two-hundred day simple moving average is $18.98. Zai Lab Limited Unsponsored ADR has a 52 week low of $15.96 and a 52 week high of $41.20. The stock has a market cap of $2.17 billion, a P/E ratio of -11.80 and a beta of 0.76.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The firm had revenue of $99.61 million for the quarter. On average, analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Zai Lab stock. Royal Bank of Canada increased its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,771 shares of the company’s stock after acquiring an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZLAB has been the subject of several research analyst reports. Citigroup cut their price target on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. JPMorgan Chase & Co. lowered their target price on Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Finally, Wall Street Zen lowered shares of Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.